112 related articles for article (PubMed ID: 9885802)
21. Somatostatin receptor imaging in non-functioning pituitary adenomas: value of an uptake index.
Duet M; Mundler O; Ajzenberg C; Berolatti B; Chedin P; Duranteau L; Warnet A
Eur J Nucl Med; 1994 Jul; 21(7):647-50. PubMed ID: 7957351
[TBL] [Abstract][Full Text] [Related]
22. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.
Bertherat J; Brue T; Enjalbert A; Gunz G; Rasolonjanahary R; Warnet A; Jaquet P; Epelbaum J
J Clin Endocrinol Metab; 1992 Aug; 75(2):540-6. PubMed ID: 1353505
[TBL] [Abstract][Full Text] [Related]
23. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
Ferone D; Lastoria S; Colao A; Varrella P; Cerbone G; Acampa W; Merola B; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
[TBL] [Abstract][Full Text] [Related]
24. The role of somatostatin receptor scintigraphy in the management of pituitary tumours.
Moulik PK; Varma TR; Vora JP; Vinjamuri S
Nucl Med Commun; 2002 Feb; 23(2):117-20. PubMed ID: 11891464
[TBL] [Abstract][Full Text] [Related]
25. Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy.
Lamberts SW; Hofland LJ; de Herder WW; Kwekkeboom DJ; Reubi JC; Krenning EP
Front Neuroendocrinol; 1993 Jan; 14(1):27-55. PubMed ID: 8097480
[TBL] [Abstract][Full Text] [Related]
26. In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analog of somatostatin ([123I]SDZ 204-090).
Faglia G; Bazzoni N; Spada A; Arosio M; Ambrosi B; Spinelli F; Sara R; Bonino C; Lunghi F
J Clin Endocrinol Metab; 1991 Oct; 73(4):850-6. PubMed ID: 1653785
[TBL] [Abstract][Full Text] [Related]
27. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
[TBL] [Abstract][Full Text] [Related]
28. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.
Krenning EP; Bakker WH; Kooij PP; Breeman WA; Oei HY; de Jong M; Reubi JC; Visser TJ; Bruns C; Kwekkeboom DJ
J Nucl Med; 1992 May; 33(5):652-8. PubMed ID: 1349039
[TBL] [Abstract][Full Text] [Related]
29. Somatostatin receptor tumor imaging (Tc 99m P829) in pituitary adenoma.
Chiewvit S; Chiewvit P; Pusuwan P; Sriussadaporn S; Ratanamart V
J Med Assoc Thai; 1999 Dec; 82(12):1208-13. PubMed ID: 10659562
[TBL] [Abstract][Full Text] [Related]
30. 111In-octreotide scintigraphy in oncology.
Krenning EP; Kwekkeboom DJ; Reubi JC; Van Hagen PM; van Eijck CH; Oei HY; Lamberts SW
Metabolism; 1992 Sep; 41(9 Suppl 2):83-6. PubMed ID: 1355591
[TBL] [Abstract][Full Text] [Related]
31. Whole body and tomographic scan with 111In-pentetreotide: preliminary data.
Gregianin M; Macrì C; Bui F; Varotto L; Zucchetta P
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):124-6. PubMed ID: 9002769
[TBL] [Abstract][Full Text] [Related]
32. Somatostatin receptor scintigraphy in patients with pituitary adenoma.
Rieger A; Rainov NG; Elfrich C; Klaua M; Meyer H; Lautenschläger C; Burkert W; Mende T
Neurosurg Rev; 1997; 20(1):7-12. PubMed ID: 9085281
[TBL] [Abstract][Full Text] [Related]
33. Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients.
Rimareix F; Grunenwald S; Vezzosi D; Rivière LD; Bennet A; Caron P
Thyroid; 2015 Aug; 25(8):877-82. PubMed ID: 26244412
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin receptor scintigraphy of a patient with a giant invasive prolactinoma.
Meyer P; Bohnen NI; Barkan AL; Shapiro B
Nuklearmedizin; 1999; 38(2):66-7. PubMed ID: 10100234
[TBL] [Abstract][Full Text] [Related]
35. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
Shimon I; Yan X; Taylor JE; Weiss MH; Culler MD; Melmed S
J Clin Invest; 1997 Nov; 100(9):2386-92. PubMed ID: 9410919
[TBL] [Abstract][Full Text] [Related]
36. Visualization of non-Hodgkin's lymphoma by high dosed somatostatin receptor specific scintigraphy and extended single photon emission tomography.
Lipp RW; Schnedl WJ; Aglas F; Ranner G; Beham-Schmid C; Leb G; Sill H
Acta Med Austriaca; 1999; 26(3):105-8. PubMed ID: 10520379
[TBL] [Abstract][Full Text] [Related]
37. Somatostatin receptors, adenylate cyclase activity, and growth hormone (GH) response to octreotide in GH-secreting adenomas.
Bertherat J; Chanson P; Dewailly D; Dupuy M; Jaquet P; Peillon F; Epelbaum J
J Clin Endocrinol Metab; 1993 Dec; 77(6):1577-83. PubMed ID: 7903312
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo evaluation of copper-64-octreotide conjugates.
Anderson CJ; Pajeau TS; Edwards WB; Sherman EL; Rogers BE; Welch MJ
J Nucl Med; 1995 Dec; 36(12):2315-25. PubMed ID: 8523125
[TBL] [Abstract][Full Text] [Related]
39. [Octreotide in the treatment of thyrotropin-secreting pituitary adenomas].
Podoba J; Hnilica P; Makaiová I; Kovácová S; Rybár M; Gecík K; Belan V; Steno J
Vnitr Lek; 1997 Sep; 43(9):607-10. PubMed ID: 9750471
[TBL] [Abstract][Full Text] [Related]
40. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]